Evaxion biotech announces closing of private placement

Copenhagen, denmark, dec. 21, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today announced the closing of its previously announced private placement (the “private placement”) with a gross proceed of $5.3 million. the private placement included participation from existing and new shareholders, with the largest new shareholder being msd global health innovation fund (msd ghi), a corporate venture capital arm of merck & co., inc., rahway, nj, usa, accounting for some 25% of the total aggregate offering amount. further, the private placement included significant participation by all members of the company's management and the company's board of directors.
EVAX Ratings Summary
EVAX Quant Ranking